Uncategorized

AnPac Bio-Medical Science Co., Ltd. announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs.

Nuance Pharma announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

Readers for Abbott’s FreeStyle Libre glucose monitoring systems could catch fire if improperly stored or charged, the FDA says.

If funding in the next three quarters matches the average funding in the prior three, 2023 is on pace to see the lowest level of digital health funding since 2019, a new report from Rock Health found.

Torrent Pharma has begun shipping the generic version of Xeris’s Keveyis® (dichlorphenamide), 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

HeartFlow’s software models a patient’s coronary arteries from imaging, which cardiologists can use to determine the best course of treatment.

Ken Reali was asked to leave after a deal to buy CartiHeal fell apart, and Bioventus’ share price dropped more than 90% in the past two years. 

Both hospital and payer groups came out in support of the rule finalized Wednesday, finding common ground in the need to streamline prior authorization.

Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.

With experienced technicians retiring faster than their replacements are getting up to speed, the sector faces a potentially costly skills challenge.